Published in Hospital Business Week, April 22nd, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at CytoCore, Inc.
Report 1: Currently ramping up for Q2 production and distribution of its suite of products for the early screening and treatment of reproductive cancers, CytoCore, Inc. (OTCBB:CYCR) today noted a comprehensive new market report projecting 41 percent annual growth in the area of molecular diagnostics and screening in the United States alone, with a market potential of $92 billion projected by 2016.
According to the newly released Kalorama Information...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.